Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19 (2022)

Peer-Reviewed Study · Hoang R, Temple C, Correia MS, Clemons J, Hendrickson RG · December 2022

Hoang R et al., 2022-12: Retrospective analysis of 37 Oregon Poison Center cases over 24 weeks, 30 of them with neurotoxicity, with higher doses and more altered mental status among those taking veterinary products. It separates acute high-dose toxicity from the milder chronic pattern at about 13.5 mg/day for a median 3.8 weeks.

Clinical effects included neurotoxicity (30), gastrointestinal symptoms (14), and musculoskeletal complaints (7).

Hoang R et al., 2022-12: Retrospective analysis of 37 Oregon Poison Center cases over 24 weeks, 30 of them with neurotoxicity, with higher doses and more altered mental status among those taking veterinary products. It separates acute high-dose toxicity from the milder chronic pattern at about 13.5 mg/day for a median 3.8 weeks. C4 poison-centre series. Study type: retrospective poison-centre case series; N=37; United States (Oregon Poison Center), 14 August 2021 to 31 January 2022. Doses: 17 ingested veterinary formulations, 15 prescription tablets; chronic users took a median daily dose of 13.5 mg for a median 3.8 weeks and had milder toxicity. Outcomes: 21 hospitalised, 13 emergency-department treated, 3 outpatient, 1 death. Comparator: veterinary vs human formulation groups; acute vs chronic ingestion. Funder and declared conflicts: not in the PubMed record. Study type: uncontrolled series.